OmniAb (OABI) to Announce Quarterly Earnings on Thursday

OmniAb (NASDAQ:OABI) is anticipated to announce its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $4.6930 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

OmniAb (NASDAQ:OABI) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.04. The business had revenue of $14.43 million during the quarter, compared to the consensus estimate of $5.60 million. OmniAb had a negative return on equity of 20.31% and a negative net margin of 187.59%. On average, analysts expect OmniAb to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

OmniAb Stock Performance

Shares of OmniAb stock traded up $0.04 on Tuesday, hitting $2.00. 26,057 shares of the company traded hands, compared to its average volume of 519,438. OmniAb has a 52 week low of $1.30 and a 52 week high of $2.79. The business has a 50-day simple moving average of $2.29 and a 200 day simple moving average of $1.95. The stock has a market capitalization of $288.84 million, a P/E ratio of -4.34 and a beta of 0.43.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of OmniAb from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 21st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $3.00.

Institutional Investors Weigh In On OmniAb

Several large investors have recently bought and sold shares of OABI. AQR Capital Management LLC bought a new stake in shares of OmniAb in the 1st quarter worth about $25,000. Osaic Holdings Inc. grew its position in OmniAb by 214.4% in the second quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock worth $25,000 after acquiring an additional 9,716 shares in the last quarter. BNP Paribas Financial Markets grew its position in OmniAb by 92.5% in the third quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock worth $35,000 after acquiring an additional 10,438 shares in the last quarter. Cerity Partners LLC increased its stake in OmniAb by 111.5% during the second quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock worth $39,000 after acquiring an additional 11,919 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in OmniAb during the fourth quarter valued at approximately $54,000. Institutional investors own 72.08% of the company’s stock.

About OmniAb

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.